White Pine Capital LLC Acquires 25,337 Shares of Johnson & Johnson $JNJ

White Pine Capital LLC bought a new position in shares of Johnson & Johnson (NYSE:JNJ – Free Report) during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor bought 25,337 shares of the company’s stock, valued at approximately $6,708,000. Johnson & Johnson makes up approximately 1.6% of White Pine Capital LLC’s portfolio, making the stock its 9th largest position.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the company. Jupiter Topco LLC purchased a new stake in Johnson & Johnson during the second quarter worth about $1,967,399,000. Corient Private Wealth LP lifted its position in shares of Johnson & Johnson by 127.3% during the second quarter. Corient Private Wealth LP now owns 6,060,922 shares of the company’s stock worth $1,539,292,000 after purchasing an additional 3,393,981 shares in the last quarter. Wellington Management Group LLP lifted its position in shares of Johnson & Johnson by 12.5% during the second quarter. Wellington Management Group LLP now owns 22,588,696 shares of the company’s stock worth $5,736,851,000 after purchasing an additional 2,513,321 shares in the last quarter. Amundi boosted its stake in shares of Johnson & Johnson by 17.5% in the first quarter. Amundi now owns 13,406,820 shares of the company’s stock valued at $3,277,163,000 after purchasing an additional 2,001,139 shares during the period. Finally, Fisher Asset Management LLC boosted its stake in shares of Johnson & Johnson by 11.5% in the third quarter. Fisher Asset Management LLC now owns 14,837,126 shares of the company’s stock valued at $3,927,981,000 after purchasing an additional 1,530,070 shares during the period. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Johnson & Johnson

In related news, EVP Timothy Schmid sold 33,597 shares of the stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $274.74, for a total value of $9,230,439.78. Following the transaction, the executive vice president owned 25,447 shares of the company’s stock, valued at $6,991,308.78. This represents a 56.90% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, EVP Elizabeth Forminard sold 13,072 shares of the firm’s stock in a transaction on Thursday, November 12th. The shares were sold at an average price of $284.39, for a total value of $3,717,546.08. Following the completion of the sale, the executive vice president owned 16,994 shares in the company, valued at approximately $4,832,923.66. This represents a 43.48% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 0.16% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on JNJ shares. Raymond James Financial set a $280.00 price objective on shares of Johnson & Johnson in a report on Monday, August 3rd. Bank of America reiterated a “neutral” rating and set a $278.00 target price on shares of Johnson & Johnson in a report on Tuesday, September 29th. Morgan Stanley decreased their price target on shares of Johnson & Johnson from $294.00 to $292.00 and set an “overweight” rating for the company in a research report on Thursday, October 15th. TD Cowen reissued a “buy” rating on shares of Johnson & Johnson in a research report on Tuesday, October 20th. Finally, JPMorgan Chase & Co. boosted their price target on shares of Johnson & Johnson from $270.00 to $285.00 and gave the stock a “neutral” rating in a research note on Tuesday, September 29th. One analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and eight have assigned a Hold rating to the stock. According to data from MarketBeat, Johnson & Johnson has a consensus rating of “Moderate Buy” and a consensus target price of $275.92.

Check Out Our Latest Research Report on JNJ

Johnson & Johnson Stock Performance

Shares of JNJ opened at $285.78 on Monday. The stock has a 50-day simple moving average of $266.97 and a 200-day simple moving average of $249.85. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.74 and a current ratio of 1.02. The stock has a market capitalization of $687.95 billion, a PE ratio of 43.30, a PEG ratio of 2.82 and a beta of 0.22. Johnson & Johnson has a 1 year low of $193.55 and a 1 year high of $288.11.

Johnson & Johnson (NYSE:JNJ – Get Free Report) last released its earnings results on Tuesday, October 13th. The company reported $2.59 earnings per share for the quarter, topping analysts’ consensus estimates of $2.53 by $0.06. Johnson & Johnson had a net margin of 16.20% and a return on equity of 31.64%. The firm had revenue of $25.40 billion for the quarter, compared to analyst estimates of $25.38 billion. During the same period in the prior year, the firm earned $2.80 earnings per share. The business’s quarterly revenue was up 5.9% compared to the same quarter last year. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. On average, analysts predict that Johnson & Johnson will post 11.12 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 8th. Stockholders of record on Tuesday, November 24th will be issued a $1.34 dividend. This represents a $5.36 dividend on an annualized basis and a dividend yield of 1.9%. The ex-dividend date is Tuesday, November 24th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 81.21%.

Trending Headlines about Johnson & Johnson

Investors following JNJ have been watching these headlines:

Johnson & Johnson Company Profile

(Free Report)

Johnson & Johnson is a global healthcare company that develops and sells prescription medicines and medical technologies. Its business is organized around two segments: Innovative Medicine and MedTech. Innovative Medicine develops treatments in areas including oncology, immunology, neuroscience, cardiovascular and metabolic disease, and pulmonary hypertension. MedTech provides products and technologies for fields such as surgery, orthopedics, and vision care. Founded in 1886, Johnson & Johnson serves patients and healthcare professionals in markets around the world.

See Also

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.